Sugi Predict

Sugi Predict / Compounds / SCHEMBL398044

SCHEMBL398044

SCHEMBL398044

Cc1ccc(S(=O)(=O)N(CCCl)CCCl)cc1

nearest known ligand 0.70

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 7/20 0.57
▸ GLA P06280 1/20 0.56
▸ MAPT P10636 1/20 0.48
▸ MCOLN3 Q8TDD5 1/20 0.48
▸ HTT P42858 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ C5AR1 P21730 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ AGER Q15109 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9310747 0.93 CNR2 (0.52) CNR2GLAMAPTMCOLN3SMN1; SMN2
SCHEMBL27989014 0.90 CNR2 (0.50) CNR2GLAMAPTMCOLN3LMNA
SCHEMBL21753821 0.85 GLA (0.54) CNR2GLAMAPTMCOLN3HTT
SCHEMBL18591589 0.84 GLA (0.59) CNR2GLAMAPTMCOLN3HTT
Ditolamide SCHEMBL2110790 0.82 CA9 (0.64) CNR2GLAHTTLMNASMN1; SMN2
SCHEMBL3626535 0.82 CA12 (0.50) CNR2GLAMAPTHTTLMNA
SCHEMBL6900864 0.81 HTT (0.51) CNR2GLAMAPTHTTLMNA
SCHEMBL4076826 0.81 CA12 (0.57) CNR2HTTLMNASMN1; SMN2NPC1
SCHEMBL898459 0.81 GLA (0.56) CNR2GLAMAPTMCOLN3HTT
SCHEMBL2362509 0.81 GLA (0.56) CNR2GLAMAPTMCOLN3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115321919-B High-performance machine-made sand concrete and preparation method thereof 河南金诺混凝土有限公司 2023-05-16 — — CN claimed
CN-115321919-A High-performance machine-made sand concrete and preparation method thereof 河南金诺混凝土有限公司 2022-11-11 — — CN claimed
WO-2013175499-A2 POLYMORPHIC FORM OF 5-(4-[4-(5-CYANO-1H-INDOL-3- YL)BUTYL]PIPERAZIN-1-YL) BENZOFURAN-2-CARBOXAMIDE CADILA HEALTHCARE LIMITED (IN) 2013-11-28 — — WO claimed
WO-2008155777-A2 PROCESS FOR PREPARING EFLETRIZINE CADILA HEALTHCARE LIMITED (IN) 2008-12-24 — — WO claimed
EP-0789699-B1 SPIRO[HETEROCYCLE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE]-4'-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME RHONE POULENC RORER SA (FR) 1999-03-17 — — EP claimed
US-5777114-A Spiro heterocycle-imidazo 1,2-a!indeno 1,2-e!pyrazine!-4'-ones, preparation thereof and drugs containing same RHONE-POULENC RORER S.A. (FR) 1998-07-07 — — US claimed
EP-0789699-A1 SPIRO HETEROCYCLE-IMIDAZO(1,2-a]INDENO(1,2-e]PYRAZINE]-4'-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME Aventis Pharma S.A. (FR) 1997-08-20 — — EP claimed
WO-1997010246-A1 INDENO[1,2-e]PYRAZIN-4-ONES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1997-03-20 — — WO claimed
WO-1996014318-A1 SPIRO[HETEROCYCLE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE]-4'-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1996-05-17 — — WO claimed
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 — — US disclosed
US-12637473-B2 MDM2 protein degraders REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-05-26 — — US disclosed
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use CARMOT THERAPEUTICS INC. (US) 2025-11-04 — — US disclosed
EP-4605395-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Dong-A ST Co., Ltd. (KR) 2025-08-27 — — EP disclosed
US-12398130-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2025-08-26 — — US disclosed
EP-0034415-B1 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1984-05-30 — — EP disclosed
US-4369184-A ANTIHISTAMINES; HETEROCYCLIC NITRILES JANSSEN PHARMACEUTICA N.V. (BE) 1983-01-18 — — US disclosed
EP-0034415-A1 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1981-08-26 — — EP disclosed
US-4259338-A Benzofuranyl-tetrahydropyridines and -piperidines, their acid addition salts and antidepressant preparations thereof CIBA-GEIGY CORPORATION (US) 1981-03-31 — — US disclosed
US-4072686-A ANTIDIARRHEAL G. D. SEARLE & CO. (US) 1978-02-07 — — US disclosed
US-4066654-A 1-TRIARYLALKYL-4-PHENYL-4-PIPERIDINE CARBOXYLIC ACIDS AND DERIVATIVES G. D. SEARLE & CO. (US) 1978-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637473-B2 MDM2 protein degraders MDM2, TP53, TP53BP1 CNR2 3724/4885GLA 964/4885MAPT 1512/4885
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use GLP1R, GCGR, GIPR CNR2 87/4885GLA 1908/4885MAPT 2926/4885
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 CNR2 554/4885GLA 3303/4885MAPT 3785/4885
US-12398130-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 CNR2 4368/4885GLA 316/4885MAPT 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.